
About this episode
Join Dr Laura Coates, Prof Enrique Soriano, Prof Chris Ritchlin, and Ass Prof Frank Behrens for our first podcast dedicated to the latest publications in PsA! In this edition, our Steering Committee members look at three key papers published in May 2022. The first, from Egeberg et al, looks at drug survival using a large, nationwide cohort study from the DANBIO and DERMBIO registries. The second looks at pooled data from SELECT-PsA-1 and -2 to investigate the safety profile of upadacitinib versus adalimumab in patients with active PsA and IR to biologic/non-biologic DMARDs. And finally, our speakers discuss new data from Merola et al on the effect of secukinumab CV risk factors and inflammatory biomarkers. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum

Author Interview: Doctor Elise van Mulligen, September 2026
The IMID Forum
Sep 3, 202621:20pending

Discussing RA: Biologic effectiveness and treatment persistence in RA
The IMID Forum
Aug 27, 20268:52pending

Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety
The IMID Forum
Aug 20, 202624:22pending

Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg,...
The IMID Forum
Aug 13, 202626:58pending